Table 2.
Novel antimicrobial Ambler class activity
| Drug | Ambler group A | Ambler group B | Ambler group C | Ambler group D | 2019 CLSI Enterobacterales MIC breakpoint |
|---|---|---|---|---|---|
| β-lactam/β-lactamase inhibitor | |||||
| Ceftazidime-avibactam | + | - | + | + (OXA-48) | 8/4 |
| Meropenem-vaborbactam | + | - | + | - | 4/8* |
| Imipenem-relebactam | + | - | + | - | 1/4** |
| Other novel antimicrobials | |||||
| Plazomicin | + | + | + | + | 2** |
| Cefiderocol | + | + | + | + | 2** |
| Fosfomycin | + | + | + | + | N/A |
*Higher than meropenem breakpoint, avoid use in OXA endemic areas
**FDA minimum inhibitory concentration breakpoint
OXA, oxacillinase; CLSI, Clinical and Laboratory Standards Institute